The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp , Johnson & Johnson , Gilead Sciences and Novartis AG , who the regulator says are potentially blocking access to samples of their drugs to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products they intend to copy, the FDA said. “I want to be very clear: a path to securing samples of brand drugs for the purpose of generic drug development should always be available,” FDA Commissioner Scott Gottlieb said in a statement.
Source: Yahoo! News